Redirecting to Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021 q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
Accelerated Cost Synergies and Achieved $2.3 Billion Target One Year Ahead of Plan
Reported Net Profit Growth of Approximately +750% YOY, Reflecting Gains on Non-core Asset Sales and Lower Acquisition-related Expenses
Robust Operating Cash Flow and Divestiture Proceeds Resulting in Free Cash Flow of JPY 1,237.8 Billion, Driving Deleveraging to Net Debt / Adjusted EBITDA of 3.2x
FY2021 Anticipated to be an Inflection Year for Wave 1 Pipeline with Five to Six Wave 1 NMEs Submitted and Under Regulatory Review by the FDA with the Potential for Four Approvals
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021).
717.5
-3.8%
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at
(2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations.
(3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.